UTHR.NASDAQUnited Therapeutics CORP
Form 4: UNITED THERAPEUTICS CEO Sells Shares
Sentiment:
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 7,580 shares of common stock on September 30, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $117.76 ($1,118,720) on September 30, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 161 Common Stock at $476.14 ($76,659) on September 30, 2026; holds 333,782 after (Indirect).
- Open-market sale: disposed of 749 Common Stock at $477.43 ($357,592) on September 30, 2026; holds 333,033 after (Indirect).
- Open-market sale: disposed of 650 Common Stock at $478.47 ($311,004) on September 30, 2026; holds 332,383 after (Indirect).
- Open-market sale: disposed of 359 Common Stock at $479.67 ($172,201) on September 30, 2026; holds 332,024 after (Indirect).
- Open-market sale: disposed of 601 Common Stock at $480.79 ($288,957) on September 30, 2026; holds 331,423 after (Indirect).
- Open-market sale: disposed of 160 Common Stock at $482.36 ($77,177) on September 30, 2026; holds 331,263 after (Indirect).
- Open-market sale: disposed of 80 Common Stock at $487.79 ($39,023) on September 30, 2026; holds 331,183 after (Indirect).
- Open-market sale: disposed of 40 Common Stock at $495.32 ($19,813) on September 30, 2026; holds 331,143 after (Indirect).
- Open-market sale: disposed of 40 Common Stock at $511.37 ($20,455) on September 30, 2026; holds 331,103 after (Indirect).
- Open-market sale: disposed of 80 Common Stock at $514.90 ($41,192) on September 30, 2026; holds 331,023 after (Indirect).
- Open-market sale: disposed of 80 Common Stock at $517.16 ($41,373) on September 30, 2026; holds 330,943 after (Indirect).
- Open-market sale: disposed of 80 Common Stock at $523.36 ($41,869) on September 30, 2026; holds 330,863 after (Indirect).
- Open-market sale: disposed of 80 Common Stock at $524.62 ($41,970) on September 30, 2026; holds 330,783 after (Indirect).
- Open-market sale: disposed of 80 Common Stock at $526.09 ($42,087) on September 30, 2026; holds 330,703 after (Indirect).
- Open-market sale: disposed of 160 Common Stock at $531.11 ($84,978) on September 30, 2026; holds 330,543 after (Indirect).
- Open-market sale: disposed of 160 Common Stock at $536.52 ($85,843) on September 30, 2026; holds 330,383 after (Indirect).
- Open-market sale: disposed of 200 Common Stock at $537.67 ($107,534) on September 30, 2026; holds 330,183 after (Indirect).
- Open-market sale: disposed of 40 Common Stock at $538.65 ($21,546) on September 30, 2026; holds 330,143 after (Indirect).
- Open-market sale: disposed of 480 Common Stock at $540.78 ($259,573) on September 30, 2026; holds 329,663 after (Indirect).
- Open-market sale: disposed of 580 Common Stock at $541.76 ($314,222) on September 30, 2026; holds 329,083 after (Indirect).
- Open-market sale: disposed of 600 Common Stock at $543.25 ($325,947) on September 30, 2026; holds 328,483 after (Indirect).
- Open-market sale: disposed of 840 Common Stock at $544.05 ($457,000) on September 30, 2026; holds 327,643 after (Indirect).
- Open-market sale: disposed of 920 Common Stock at $545.13 ($501,519) on September 30, 2026; holds 326,723 after (Indirect).
- Open-market sale: disposed of 360 Common Stock at $546.23 ($196,644) on September 30, 2026; holds 326,363 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on September 30, 2026; holds 328,410 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $3,926,177 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-30 | Option exercise/conversion | Common Stock | 9,500 | $118 | $1.1M | 333,943 |
| 2026-09-30 | Open-market sale | Common Stock | 161 | $476 | $76.7K | 333,782 |
| 2026-09-30 | Open-market sale | Common Stock | 749 | $477 | $357.6K | 333,033 |
| 2026-09-30 | Open-market sale | Common Stock | 650 | $478 | $311.0K | 332,383 |
| 2026-09-30 | Open-market sale | Common Stock | 359 | $480 | $172.2K | 332,024 |
| 2026-09-30 | Open-market sale | Common Stock | 601 | $481 | $289.0K | 331,423 |
| 2026-09-30 | Open-market sale | Common Stock | 160 | $482 | $77.2K | 331,263 |
| 2026-09-30 | Open-market sale | Common Stock | 80 | $488 | $39.0K | 331,183 |
| 2026-09-30 | Open-market sale | Common Stock | 40 | $495 | $19.8K | 331,143 |
| 2026-09-30 | Open-market sale | Common Stock | 40 | $511 | $20.5K | 331,103 |
| 2026-09-30 | Open-market sale | Common Stock | 80 | $515 | $41.2K | 331,023 |
| 2026-09-30 | Open-market sale | Common Stock | 80 | $517 | $41.4K | 330,943 |
| 2026-09-30 | Open-market sale | Common Stock | 80 | $523 | $41.9K | 330,863 |
| 2026-09-30 | Open-market sale | Common Stock | 80 | $525 | $42.0K | 330,783 |
| 2026-09-30 | Open-market sale | Common Stock | 80 | $526 | $42.1K | 330,703 |
| 2026-09-30 | Open-market sale | Common Stock | 160 | $531 | $85.0K | 330,543 |
| 2026-09-30 | Open-market sale | Common Stock | 160 | $537 | $85.8K | 330,383 |
| 2026-09-30 | Open-market sale | Common Stock | 200 | $538 | $107.5K | 330,183 |
| 2026-09-30 | Open-market sale | Common Stock | 40 | $539 | $21.5K | 330,143 |
| 2026-09-30 | Open-market sale | Common Stock | 480 | $541 | $259.6K | 329,663 |
| 2026-09-30 | Open-market sale | Common Stock | 580 | $542 | $314.2K | 329,083 |
| 2026-09-30 | Open-market sale | Common Stock | 600 | $543 | $325.9K | 328,483 |
| 2026-09-30 | Open-market sale | Common Stock | 840 | $544 | $457.0K | 327,643 |
| 2026-09-30 | Open-market sale | Common Stock | 920 | $545 | $501.5K | 326,723 |
| 2026-09-30 | Open-market sale | Common Stock | 360 | $546 | $196.6K | 326,363 |
| 2026-09-30 | Option exercise/conversion | Stock Option | 9,500 | — | — | 328,410 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-30 | Option exercise/conversion (9,500 shares) |
| 2026-09-30 | Open-market sale (161 shares) |
| 2026-09-30 | Open-market sale (749 shares) |
| 2026-09-30 | Open-market sale (650 shares) |
| 2026-09-30 | Open-market sale (359 shares) |
| 2026-09-30 | Open-market sale (601 shares) |
| 2026-09-30 | Open-market sale (160 shares) |
| 2026-09-30 | Open-market sale (80 shares) |
| 2026-09-30 | Open-market sale (40 shares) |
| 2026-09-30 | Open-market sale (40 shares) |
| 2026-09-30 | Open-market sale (80 shares) |
| 2026-09-30 | Open-market sale (80 shares) |
| 2026-09-30 | Open-market sale (80 shares) |
| 2026-09-30 | Open-market sale (80 shares) |
| 2026-09-30 | Open-market sale (80 shares) |
| 2026-09-30 | Open-market sale (160 shares) |
| 2026-09-30 | Open-market sale (160 shares) |
| 2026-09-30 | Open-market sale (200 shares) |
| 2026-09-30 | Open-market sale (40 shares) |
| 2026-09-30 | Open-market sale (480 shares) |
| 2026-09-30 | Open-market sale (580 shares) |
| 2026-09-30 | Open-market sale (600 shares) |
| 2026-09-30 | Open-market sale (840 shares) |
| 2026-09-30 | Open-market sale (920 shares) |
| 2026-09-30 | Open-market sale (360 shares) |
| 2026-09-30 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.